AN9025 is an oral small molecule pan-RAS(ON) inhibitor designed to address a broad range of RAS mutations across multiple tumor types. The first patient has been dosed in early February 2026 in the ongoing global Phase 1 clinical trial in the US and China, with dose escalation anticipated to be completed in H1 2027.

AN9025 demonstrates superior potency compared to a clinical benchmark pan-RAS(ON) inhibitor sharing the same mechanism of action, driving potent and broad-spectrum anti-tumor activity in both in vitro and in vivo models.

AN9025 inhibits the viability of RAS-addicted cancer cell lines

Antitumor effects of AN9025 in KRAS-driven xenograft mice models

AN9025 exhibited a therapeutic index comparable to or slightly superior to that of RMC-6236 in a QD regimen, despite its significantly greater potency.

Reference

1. AN9025, an orally bioavailable pan-RAS(ON) inhibitor with potent, broad-spectrum anti-tumor activity, AACR 2025